Sibutramine is the first of a new generation of weight management drugs, and offers long-term control of weight when used as an adjunct to diet and exercise. This paper considers the criteria set down by the European Union's regulatory agency for its use and how this relates to the information now available on its efficacy, side-effect profile and benefits in different patient groups. The data presented relate to 18 -65 y olds; its use in other age groups has not been established. The EU licence permits continuous treatment for periods of up to 1 y; the STORM study has now led the US Food and Drug Administration to extend clearance to 2 y. The addition of sibutramine to a regimen of diet, exercise and lifestyle modification results in 3 -5 times more patients responding to a weight-reduction programme, ie achieving more than 5% weight maintenance. Sibutramine is indicated for use in obese patients (BMI > 30 kg=m 2 ) and also overweight patients with a BMI > 27 kg=m 2 who have additional obesity-related risk factors such as type 2 diabetes or dyslipidaemia. International Journal of Obesity (2001) 25, Suppl 4, S2 -S7.
Introduction
The classical non-invasive techniques for weight reduction, namely diet, behaviour modification and exercise, remain the cornerstone for the management of obesity, but in most doctors' experience, there are very poor long-term outcomes. Sibutramine is the first of a new generation of weight management drugs for use in the long-term control of weight. Sibutramine was launched in the USA in February 1998 with the first European launch in Germany in February 1999; by March 2001, sibutramine was available in approximately 50 countries worldwide. This paper considers the criteria set by the European Regulatory Authority for the use of sibutramine and how this relates to clinical data currently available. More detailed reviews of sibutramine's unique mode of action are provided in the paper by Lean, its proven clinical efficacy in uncomplicated obesity in the paper by Finer, its use in obese=over-overweight subjects with comorbidities such as dyslipidaemia and type 2 diabetes in the paper by Van Gaal and Peiffer and in controlled hypertensives in the paper by Sharma.
Therapeutic indications
According to the European Union (EU) label, sibutramine 10 mg and sibutramine 15 mg are indicated as adjunctive treatment within a weight management programme for obese patients with a body mass index (BMI) of 30 kg=m 2 or higher. Overweight patients with a BMI of 27 kg=m 2 or higher may also be treated with sibutramine, if other obesityrelated risk factors such as type 2 diabetes or dyslipidaemia are present. All patients must have tried to lose weight (albeit unsuccessfully) with a non-pharmacological weight management programme before starting treatment with sibutramine. Unsuccessful weight loss is considered to be < 5% weight loss over a 3 month, active-management period.
Dose considerations
Sibutramine is available in two dosage strengths, 10 and 15 mg. All patients should be started on a once-daily regimen at the lower of the two recommended doses, ie 10 mg=day. This dose, if well tolerated, can be increased to 15 mg=day in patients who respond inadequately (ie experience weight loss of < 2 kg after 4 weeks on treatment). In those patients who fail to respond to this higher dose (ie do not lose 2 kg after a second 4 week period) treatment with sibutramine should be withdrawn.
This proposal was based on a dose-ranging study, 1 which showed that 10 mg daily sibutramine, combined with a 600 kcal=day deficit diet, provides an effective and welltolerated regimen (see Figure 1) . Although both the 10 and 15 mg dose levels are well tolerated, it is standard medical practice to commence at the lower dose in order to minimise any potential adverse reactions, especially on blood pressure and heart rate, and thus comply with the EU label.
The 2 kg weight loss at 1 month is used as a decision point for continuing treatment with sibutramine. Data from individual patients show that the long-term efficacy of sibutramine can be predicted, with a high degree of accuracy, based on this criterion of early weight loss. Conversely, patients who do not lose 2 kg at 1 month do not tend to achieve this degree of weight loss with continued sibutramine treatment. Obese patients with type 2 diabetes typically find it harder to achieve weight loss per se and, in particular, are slow to lose weight; hence, these cut-off points for early prediction of response are different in obese diabetic patients. Studies have shown that even diabetic patients who are not achieving 1 kg weight loss at 1 month can still achieve clinically important weight loss after 12 months on sibutramine treatment. However, the EU label does not distinguish between patients with and without co-morbidities and the criterion of 2 kg at 1 month applies to all patients to minimise exposure of non-responders in terms of weight loss to potential blood pressure and heart rate changes (see paper by Finer).
Ancillary therapy
According to the EU label, in both uncomplicated obese patients and overweight patients with comorbidities, sibutramine therapy should be part of a long-term programme of weight reduction strategies, based on dietary and lifestyle modification including exercise. This is consistent with a range of weight management studies, conducted with sibutramine, which shows that the more specific, coherent and sustained the support in ensuring changes in lifestyle with lowered energy intakes and increases in physical activity, the greater the benefit from the additional use of sibutramine. The requirement for an integrated management scheme is also consistent with the well recognised benefits of ensuring changes in diet, eg lowered fat and sugar intakes and more fruit, vegetables and whole grain products, and greater physical exercise and conform with current national guidelines for the treatment of obesity. Data from a specific study by Wadden et al 2 confirmed the value of these guidelines with the use of sibutramine (see Figure 2 ). This study conducted in 53 obese women (mean BMI 37.7 kg=m 2 ) showed that the percentage reduction in initial weight achieved after 12 months' sibutramine treatment was dependent on the level of ancillary therapy (diet and exercise) provided.
Three groups of patients were given either:
1. Sibutramine (10 mg titrated to 15 mg, if tolerated) plus a balanced diet (1200 -1500 kcal=day) plus exercise 30 -40 min 4 -5 times per week. 2. As 1 above plus lifestyle modification.
As 2 above but with calorie restriction (1000 kcal=day).
The results demonstrated that weight loss is greater and better maintained in those patients also treated with ancillary therapy.
Treatment duration
The EU label states that patients responding well to sibutramine may be treated continuously for periods of up to 1 y, as part of an on-going weight loss and weight maintenance programme that includes diet and exercise. Treatment should be discontinued in those patients whose weight loss stabilises at less than 5% of their initial body weight after 3 months on treatment, or in those who regain more than 3 kg of an initial weight loss. This latter, and somewhat subjective, criterion may be considered illogical in a patient who has successfully lost a significant amount of total body Use of sibutramine A Astrup and S Toubro weight on treatment with sibutramine. Nevertheless, the physician has the discretion to continue treatment if he or she believes that it is having a positive impact on comorbidities. In practice, weight regain should highlight the need to re-evaluate the intake and exercise pattern of the patient and to seek new ways of increasing activity and reducing intake.
In the USA, continuous treatment with sibutramine is allowed for periods of up to 2 y. The reason for the discrepancy is because the EU Regulatory Authorities have not taken into full consideration the results of the recent STORM trial. 3 These data demonstrate that sibutramine is safe and effective for up to 2 y. In the EU, patients after a year's treatment with sibutramine should continue to be monitored and then reassessed as to their suitability before recommencing a further period of long-term weight management using sibutramine.
Which patients should not use sibutramine?
The majority of the patients who should not be treated with sibutramine relate either to its mode of action as a noradrenaline and 5-HT monoamine reuptake inhibitor (see the paper by Lean) or to the fact that a particular patient population has not been investigated in controlled clinical trials. For example, no data are available for patients aged < 18 or > 65 y, for those with severely compromised hepatic or renal function or for women who are pregnant or lactating. Patients with a history of major eating disorders, psychiatric illness or a history of drug=alcohol abuse should not be treated. Those patients who are being treated with a monoamine oxidase inhibitor (or have been within the last 2 weeks) or those on other centrally acting drugs also should not receive sibutramine. Because of sibutramine's potential effects on blood pressure and heart rate (see paper by Sharma) and=or because of the absence of data, patients with phaeochromocytoma, a history of cardiovascular or cerebrovascular disease, tachycardia, peripheral arterial occlusive disease or arrhythmia should not be treated. Patients with controlled hypertension may be treated with sibutramine (see paper by Sharma). Some conditions, such as narrow angle glaucoma, are excluded due to the perceived drug-class contraindications, which meant that these patients were excluded from all trials with sibutramine.
What does sibutramine deliver over the long term?
The STORM study was a double-blind, randomised trial designed to assess the effect of sibutramine treatment in combination with diet and exercise on the maintenance of weight loss over a 2 y period. It provides evidence for the long-term efficacy and tolerability of this novel weight management agent (see Figure 3) .
During the 6 month open phase (when all patients received sibutramine 10 mg in combination with a comprehensive diet and exercise programme), patients had a mean weight loss of 11.9 kg. When patients subsequently were randomised for an additional 18 month treatment phase with either sibutramine or placebo, a clear divergence in outcome becomes evident, distinguishing patients on diet and exercise alone (placebo) and those receiving daily sibutramine, in addition to the same diet and exercise. The significant improvement in weight loss in sibutramine-treated patients was sustained over the 2 y study period, with some 69% of obese patients still enjoying a weight loss of at least 5% 24 months after the start of the programme. As described in greater detail in later papers within this supplement, the weight loss induced by sibutramine was accompanied by (amongst other) statistically significant and clinically relevant improvements in lipid profiles.
When data from six 12 month studies of sibutramine therapy vs control management (diet and exercise alone) were pooled, there was an approximately three-fold improvement in weight loss attributable to daily sibutramine therapy in obese patients and overweight patients with comorbidities (see Figure 4) . While around 24% of control subjects achieved 5% weight loss over the study period, this figure increased to 63% in sibutramine-treated patients. For patients achieving > 10% weight loss, the control and sibutramine responders were 8 and 31%, respectively. 4 
Sibutramine treatment in patients with obesityrelated risk factors
In obese=overweight patients (BMI > 27 mg=kg 2 ) with comorbidities, the EU label states that treatment should be continued only if the weight loss induced by sibutramine is associated with additional clinical benefits; for example, improvement in blood lipids in patients with dyslipidaemia, or improvement in glycaemic control in patients with type 2 diabetes.
Sibutramine is an effective and well-tolerated adjunctive therapy capable of promoting marked weight loss in combination with diet and exercise in overweight=obese patients with comorbidities (see paper by Van Gaal and Peiffer). A meta-analysis of studies conducted in patients with type 2 diabetes showed that patients treated with 15 mg sibutramine per day had significantly (P < 0.001) greater weight loss than patients managed with the same diet and exercise alone. 4 Over 50% of sibutramine patients, as compared with less than 20% of control subjects, achieved 5% weight loss. This marked difference between treatment groups was also evident in the proportion of patients achieving > 10% weight loss -nearly 20% of sibutramine patients as compared with only 4% of control subjects.
Thus, in overweight patients with diabetes, 3 -5 times as many sibutramine patients lost 5 and 10% in weight compared with control. The improvement in weight induced by sibutramine treatment was accompanied by clinically relevant and statistically significant beneficial improvements in HbA 1c levels within the group of patients who achieved the greatest weight loss, ie > 10% weight loss (see Figure 5 ). This significant change in HbA 1c (P < 0.01) as compared with control reflects improvements in glycaemic control associated with weight loss. 5 Studies in obese patients with dyslipidaemia also confirm that the reduction in body weight induced by sibutramine treatment is associated with an improvement in lipid profiles. A meta-analysis of lipid profile changes in all placebocontrolled studies conducted with sibutramine 10 mg once daily revealed a correlation between weight loss, a decrease from baseline in triglyceride levels and an increase from baseline of HDL (high density lipoprotein) cholesterol (see Table 1 ). Because of sibutramine's mode of action as a monoamine reuptake inhibitor (see paper by Lean), it is to be expected that there may be some effects on blood pressure and heart rate. Accordingly, the EU label recommends routine blood pressure and pulse rate monitoring for weight reduction programmes that include sibutramine therapy. In the first 3 months of the programme, blood pressure and pulse rate should be monitored every 2 weeks, with further assessments monthly during months 4 -6 of treatment. After 6 months, this monitoring should continue at 3-month intervals (see paper by Sharma for information on how simple rules for blood pressure monitoring ensure that a true assessment of any blood pressure change is made). Clinical data suggest that the cardiovascular effects of sibutramine are minor in the great majority of patients and occur early after starting treatment with sibutramine. Any untoward effects can be easily detected with the proposed monitoring schedule. Patients should be discontinued from sibutramine if drug treatment is associated with rises in resting heart rate of greater than 10 beats per minute, or where systolic or diastolic blood pressure rises more than 10 mmHg at two consecutive visits.
Sibutramine is not contraindicated in patients with controlled hypertension and, as the evidence suggests, this offers clinical benefits to most obese hypertensive patients (see paper by Sharma). Nevertheless, the label provides a cautionary statement that if previously well-controlled hypertensive patients experience blood pressure values of greater than 145=90 mmHg at two consecutive visits, then sibutramine therapy should be discontinued.
Some of the restrictions imposed by the EU Regulatory Agency relate to adverse events seen in other centrally acting agents, eg dexfenfluramine, that promote weight loss, for example, primary pulmonary hypertension or valvulopathy. In spite of the fact that clinical data with sibutramine have shown no similar evidence of an association, the EU label recommends that symptoms such as progressive dyspnoea, chest pain and ankle oedema should also be monitored in all patients during routine visits.
Side-effect and safety profile
Other side effects explicitly mentioned in the label include those concerning the central nervous system, ie dry mouth, insomnia, light-headedness, paraesthesia, headache and anxiety. Sweating and taste perversion are also included. These adverse events are largely predictable from the pharmacological activity of sibutramine and extensive clinical evaluation has shown sibutramine to be a well-tolerated agent. However, the label notes that these side effects diminish in severity and frequency over time, are generally not serious, are reversible and do not require the discontinuation of treatment.
Cardiovascular side effects such as tachycardia, palpitations and rises in blood pressure may be detected by the recommended programme of monitoring described by Sharma (this volume), and in the majority of cases these effects are mild and do not require any modification to the patient's treatment regimen.
Potential interactions
The number of drugs that may potentially interact with sibutramine is low. However, as sibutramine inhibits the reuptake of serotonin (among other effects), it should not be used concomitantly with other drugs that also raise serotonin levels in the brain. This is due to the phenomenon known as the 'serotonin syndrome' which can occur with the simultaneous use of several drugs, each of which increases the level of serotonin in the brain, and may give rise to serious interactions. This syndrome can occur in rare cases in connection with the simultaneous use of a selective serotonin reuptake inhibitor (SSRI) together with certain antimigraine drugs, or with certain opioids, or in the case of simultaneous use of two SSRIs.
Sibutramine and orlistat
Some important differences exist between the EU labels for sibutramine and another recently available pharmacotherapy for obesity and overweight, the lipase inhibitor orlistat. For example, when treatment is initiated, patients receiving orlistat must have demonstrated diet-induced weight loss of 2.5 kg one month before its use. Patients receiving sibutramine must have failed to lose weight on diet and exercise any time in the past.
In terms of dose and titration, orlistat must be taken with every meal whereas the single daily dose of sibutramine (10 and 15 mg) can be taken at any time with or without food. Finally, orlistat can be used for no longer than 2 y while sibutramine is licensed in the EU for up to 12 months, although, as we have seen, the US authorities now allow treatment to be maintained for periods of up to 2 y with both orlistat and sibutramine.
Summary
Sibutramine belongs to an entirely novel class of centrally acting anti-obesity agents and has been shown in extensive clinical trials to be a therapy well suited to adjunctive use Use of sibutramine A Astrup and S Toubro within a weight management programme to promote weight reduction in both obese patients and overweight patients with comorbidities. The addition of sibutramine to a regimen of diet and exercise can result in between three and five times more patients responding to a weight reduction programme. Sibutramine is suitable for use in patients with a BMI 30 kg=m 2 who have failed to respond to diet and exercise alone and is also indicated for use in overweight patients with a BMI 27 kg=m 2 who have additional obesityrelated risk factors, such as type 2 diabetes and dyslipidaemia. Clinical studies have shown that as many as 60% of patients achieve a greater than 5% weight loss on sibutramine therapy, and that weight loss is accompanied by positive improvements in glycaemic control and lipid profiles in patients with comorbidities. Treatment with sibutramine helps patients to sustain and maintain their weight loss. Clinical data show the superiority of sibutramine programmes over diet and exercise alone for up to 2 y. The addition of sibutramine to the physician's armament offers a new weapon in the battle to manage obesity and its inherent risks to health and well-being and it can now be used within the EU as well as elsewhere.
